תרוצידין D

ישראל - עברית - Ministry of Health

קנה את זה

עלון מידע עלון מידע (PIL)

01-12-2020

מרכיב פעיל:
CHLORAMPHENICOL; DEXAMETHASONE SODIUM PHOSPHATE; POLYMYXIN B SULFATE
זמין מ:
TARO PHARMACEUTICAL INDUSTRIES LTD
קוד ATC:
S01CA01
טופס פרצבטיות:
טיפות עיניים
הרכב:
CHLORAMPHENICOL 2 MG/ML; DEXAMETHASONE SODIUM PHOSPHATE 0.25 MG/ML; POLYMYXIN B SULFATE 2500 U/ML
מסלול נתינה (של תרופות):
עיני
סוג מרשם:
מרשם נדרש
תוצרת:
TARO PHARMACEUTICAL INDUSTRIES LTD
קבוצה תרפויטית:
DEXAMETHASONE AND ANTIINFECTIVES
איזור תרפויטי:
DEXAMETHASONE AND ANTIINFECTIVES
סממני תרפויטית:
For the treatment of serious superficial ocular infections due to strains of microorganisms susceptible to chloramphenicol and/or polymyxin B sulphate.
מספר אישור:
016 45 21224 00
תאריך אישור:
2011-05-31

מסמכים בשפות אחרות

עלון מידע עלון מידע - אנגלית

01-12-2020

עלון מידע עלון מידע - ערבית

01-12-2020

˙ÂÙ¯˙†¨‰Ó˜‡ς†„‚†˙ÂÙ¯˙†¨ÌˆÚ‰†ÁÓ†˙‡†˙‡΄Ӊ†˙ÂÙ¯˙†∫˙‡·‰

ÆÔÈÚφ¯Á‡†¯È˘Î˙†ÏΆÔÈÙ¯ˇ†„ÁÂÈÓ·†˙ÂÈ‚¯ÈÏÂÎÈË‡ ‰·†

˘ÂÓÈ˘‰†

ÔÓÊ·†

¨‰Ù¯˙‰†

Ï˘†

‰Èˆ¯‰†

˙ÂÏÈÚÙφ

ÛÒÂ·†

∫ȇÂÂφ

˙ÂÁÈÙ†

¨˙ÂÈÓÂÓ„‡†

¨„¯‚†

¨‰·È¯ˆ†

∫˙„ÁÂÈÓ†

˙ÂÒÁÈÈ˙‰†

˙·ÈÈÁÓ‰†

‰ÈÏÚ†

¨ÔÈÚ·†

·‡Î†

¨‰Ù¯˙·†

˘ÂÓÈ˘‰†

ÈÙφ

‰È‰†

‡Ï˘†

¯Á‡†

ȯȂ†

ÔÓÈÒ†

ÏΆ

¨Ô¯‚†

·‡Î†

¨¯ÂÂÈÁ†

¯ÂÚ†

ƇÙ¯φ

È؉Ù†

ÏÂÙÈˉ†

ÈؘÒÙ‰†

∫®¯È„©†

ÈÈÚ†

ÍÂ˙‰†

‡Ù¯φ

È؉Ù†

ÏÂÙÈˉ†

ÈؘÒÙ‰†

∫®¯È„©†

‰˘ÏÂÁ†

‡†

˙ÂÙÈÈÚ†

¨ÏÈ‚¯†

‡Ï†

ÌÂÓÈ„†

¨‰È‡¯·†

˙ÂÚ¯Ù‰†

Æ®ÏÂÙÈˉ†

ÌÂÈÒ†

¯Á‡Ï†

Ì‚†

ÚÈÙ‰φ

˙ÂÏÂÏÚ†

Âχ†

°„ÈÓ†‡Ù¯φÈ؉Ù†ÏÂÙÈˉ†ÈؘÒÙ‰†∫®¯È„©†˙‡˜‰Â†˙ÂÏÈÁ· ̇†

‡†

¨‰Ê†

ÔÂÏÚ·†

ÂÈȈ†

‡Ï˘†

ȇÂÂφ

˙ÂÚÙÂ˙†

‰Ø˘È‚¯Ó†

Íȉ†

·˘†

‰¯˜Ó†

Æ„ÈÓ†‡Ù¯‰†ÌÚ†ıÚÈÈ˙‰Ï†ÍÈÏÚ†˙ÈÏÏΉ†Í˙˘‚¯‰·†ÈÂÈ˘†ÏÁ Á„φ

Ìȯ‰‰†

ÏÚ†

∫˙˜ÂÈ˙†

ÌÈ„ÏÈ

·†

˙ÂÈ˙Ù¯˙†

ÔÈ

·†

˙·‚˙†

ȇÂÂφ

°‰Ø„ÏÈφ

˙˙È‰†

˙ÙÒÂ†

‰Ù¯˙†

ÏΆ

ÏÚ†

ÔΆ

ȇÂÂφ

˙ÚÙÂ˙†

ÏΆ

ÏÚ†

ÏÙËÓ‰†

ÆÂ˯ÂÙ˘†˙„ÁÂÈÓ†˙ÂÈ˙Ù¯˙†ÔÈ·†˙·‚˙†ȇÂÂφ˙ÂÚÙÂ˙†ÏÈÚφÈ؉‡¯ ‰Ó‰†

ÏÚ†

¯Â·Úφ

Ôȇ†

Æ„·Ï·†

‡Ù¯‰†

˙‡¯Â‰†

ÈÙφ

Ìȯ‚·Ó†

ÌÈ„ÏÈφ

ÔÂÈÓ†

·ˆÓ‰†

¯ÈÓÁ‰†

̇†

‡†

ÈÓȆ

μ≠∑†

ÍÂ˙†

Í·ˆÓ·†

¯ÂÙÈ˘†

ÏÁ†

‡Ï†

̇†

Ú·˜˘†

ÈÙΆ

Ìȷˆ˜†

ÌÈÓÊ·†

Âʆ

‰Ù¯˙·†

˘Ó˙˘‰Ï†

˘È†

ƇÙ¯φ

˙ÂÙφ

˘È†

¨·Âˆ˜†

ÔÓÊ·†

Âʆ

‰Ù¯˙·†

˘Ó˙˘‰Ï†

˙Á΢†

̇

ÆÏÙËÓ‰†

‡Ù¯‰†

°„ÁÈ·†˙ÂÓ†È˙˘·†˘Ó˙˘‰Ï†Ôȇ†ÔÙ‡†Ì¢·†Í‡†ª˙¯ÎÊ˘Î†„ÈÓ†˘Ó˙˘‰Ï

Æ„·Ï·†ÈˆÈÁ†˘ÂÓÈ˘Ï†˙„ÚÂÈÓ†Âʆ‰Ù¯˙†°ÚÂϷφ‡Ï†

ÏÚ†

ÈØ·Î˘†

‡†

¨¯ÂÁ‡Ï†

͢‡¯†

È؉ˉ†

ÆÍȄȆ

˙‡†

·Ëȉ†

ÈØıÁ¯†

∫˘ÂÓÈ˘‰†

Á¯Ӊ†ÍÂ˙φ¨ÔÈÚ‰†ÔÓ†ÔÂ˙Á˙‰†ÛÚÙÚ‰†˙‡†ÈؘÁ¯‰†Ú·ˆ‡‰†˙¯Êڷ†‰ËÈÓ ÆÈØÛÚÙÚ˙†

χ†

Æ˙˜„†

±≠≤†

͢Óφ

ÌÈÈÈÚ‰†

ÈØ̈چ

‰Ù¯˙‰†

˙‡†

ÈØÛËÙˆ

ÌÚ†

Ú‚Ó·†

‡Â·˙†

‡Ï†

˜Â·˜·‰†

˙ÈÈÙ˘†

È؄٘‰†

≠†

‰ÒÈÓ˙‰†

̉Èʆ

˘Ó˙˘‰Ï†

Ôȇ†

Æ·Ëȉ†

˜Â·˜·‰†

Èد‚Ò†

ÔÈÚ‰†

‡†

Ú·ˆ‡‰†

ÏÏÂΆ

¨Â‰˘ÏΆ

Ɖ¢‡¯Ï†˜Â·˜·‰†˙ÁÈ˙Ù†¯Á‡Ï†ÌÈÓȆ˘„ÂÁÓ†¯˙ÂȆ‰Ù¯˙·

øÏÂÙÈˉ†˙Áψ‰Ï†ÚÈÈÒφÈØÏÎÂ˙†„ˆÈÎ ·ˆÓ·†¯ÂÙÈ˘†ÏÁ†Ì‡†Ì‚†Æ‡Ù¯‰†È„È≠ÏÚ†ıÏÓ‰˘†ÏÂÙÈˉ†˙‡†ÌÈÏ˘‰Ï†ÍÈÏÚ

ƇÙ¯†ÌÚ†˙ˆÚÈÈ˙‰†‡Ïφ‰Ù¯˙·†ÏÂÙÈˉ†˜ÈÒىφÔȇ†Í˙‡ȯ· ıÂÁÓ†

¯Â‚Ò†

̘ӷ†

¯ÂÓ˘Ï†

˘È†

˙¯Á‡†

‰Ù¯˙†

ÏΆ

Âʆ

‰Ù¯˙†

°

Ï

Ú

¯

†È

Ø

Ú

ƉÏÚ¯‰†ÈØÚÓ˙†ÍΆȄÈ≠ÏÚ†˙˜ÂÈ˙†Â‡Ø†ÌÈ„ÏÈ†Ï˘†Ì„Ȇ‚˘È‰Ï ¯„Áφ

„ÈÓ†

È؉Ù†

¨‰Ù¯˙‰†

ÔÓ†

„ÏȆ

ÚÏ·†

˙ÂÚË·†

‡†

‡†

˙Ȇ

Ó†

ÏË†

‡Ïφ

¯

ÔÈ

ÆÍ˙ȇ†

‰Ù¯˙‰†

˙Êȯ‡†

È؇·‰Â†

ÌÈÏÂÁ≠˙È·†

Ï˘†

¨˙دÁ‡†

‰ÏÂÁ·†

¨Í˙ÏÁÓ·†

ÏÂÙÈËφ

‰Ó˘¯†

Âʆ

‰Ù¯˙

°‡Ù¯ӆ

˙˘¯ÂÙÓ†

ÂË

ÈÏ

ÔÈ

†ÆÍȯÎÓ†

‡†

ÍÈ΢†

¨ÍÈ

·Â¯˜Ï†

Âʆ

‰Ù¯˙†

ÈØÔ˙˙†

χ

ƘÈʉφ

‰ÏÂÏÚ†

ƉÙ¯˙†˙ØÏËÂ†Íȉ˘†

·†‰Ӊ†˙ÈÂÂ˙‰†˜Â„·Ï†˘È†°

ÂÁ

ÂÙ

¯

Æ̉φ‰Ø˜Â˜Ê†Íȉ†Ì‡†ÌÈÈÙ˜˘Ó†·Èί‰Ï†˘È ÌÂÈÓ†

„ÂÁ†

„Ú†

‰Ê†

¯È˘Î˙·†

˘Ó˙˘‰Ï†

˘È†

Æ®≤≠∏

©†

¯¯˜Ó·†

ÔÒÁ‡Ï†

‰Ù˜˙φ

˙Â¯Ó˘†

˙ÂÙ¯˙†

¨ÌȈÏÓÂÓ‰†

‰ÒÁ‡‰Ø‰Êȯ‡‰†

ȇ˙†

ÈÙφ

Ì‚†

Ï˘†‰¯˜Ó†Ïη†°¯È˘Î˙‰†Ï˘†‰‚ÂÙ˙‰†

Íȯ‡˙φ·Ï†ÌÈ˘Ï†‡†Æ„·Ï·†˙Ï·‚ÂÓ Æ‰Ù¯˙‰†˙‡†Íφ˜ÙÈÒ˘†Á˜Â¯·†ıÚÂÂȉφÍÈÏÚ†¨˜ÙÒ

ƉÊȯ‡†‰˙‡·†˙Â¢†˙ÂÙ¯˙†ÔÒÁ‡Ï†Ôȇ

±∂¥μÆ≤±≤≤¥†

Æ≤∂±±∞†‰ÙÈÁ†ı¯ÙÓ†±∞≥¥∑†Æ„Æ˙†¨Ó¢Ú·†˙ÈÁ˜Â¯†‰È˘Ú˙†Â¯˙†

∫Ô¯ˆÈ

±

π

†≠

†Â

¢

Ó

˘

˙

†®

Ì

ȯ

È˘

Î

˙

© †Ì

ÈÁ

˜

 ¯

†˙

Â

˜

˙

†È

Ù

Ï

†Ô

Î

¯

ˆ

Ï

†Ô

 Ï

‡Ù¯†Ì˘¯Ó·†˙·ÈÈÁ†Âʆ‰Ù¯˙ ‰Ù¯˙·†ÈØ˘Ó˙˘˙†Ì¯Ë·†ÂÙÂÒ†„Ú†ÔÂÏÚ‰†˙‡†ÔÂÈÚ·†È؇¯˜ „ȆÏÚ†¯˘Â‡Â†˜„

·†ÂÎÂ˙†˙‡ȯ

·‰†„¯˘Ó†È¢Ú†Ú·˜†‰Ê†ÔÂÏÚ†ËÓ¯ÂÙ ÌÈÈÈÚ†˙ÂÙÈË

†† D

ÔȄȈ¯˙ ∫ÏÈÎÓ†

D

†ÔȄȈ¯˙

†˙ÂÙÈË†Ï˘†Ï¢Ó†ÏÎ

ic acid, sodium

†††††††††††††††††

†††††††††††††††††††††††††††††††††

, meth

ylpar

aben, prop

ylpar

aben, w

ater f

or injection.

ÆÈËÂÈ·ÈË‡†¯ÓÂÁ†‡Â‰ Ƅȇ¯ËÒ˜È˯˜†‡Â‰ †˙ˆÂ·˜Ó†ÈËÂÈ·ÈË‡†¯ÓÂÁ†‡Â‰

ÆÌÈ„ÈʘÈÏ‚ÂÈÓ‡‰ ÌȘ„ÈÈÁ†È„È≠ÏÚ†˙ÂÓ¯‚‰†ÌÈÈÈÚ·†

˙ÂÙȯÁ†˙ÂÈÓ‰Èʆ˙˜τ·†ÏÂÙÈËφ

ÆËÙÏÂÒ†

†ÔÈÒ˜ÈÓÈÏÂÙφ‡Ø†Ï˜ÈÙÓ¯ÂÏÎφÌÈ˘È‚¯‰

ÒÙ¯‰†

¨ÈÙÈ‚†

¨È˙ÈȯËÙ†

ÌÈÈÈÚ†

̉Èʆ

∫Ï˘†

Ìȯ˜Ó·†

Âʆ

‰Ù¯˙·†

˘Ó˙˘‰Ï†

˙Ϸ҆‡†˙ØÏ·ÂÒ†Íȉ†Ì‡†Â‡†

˙È¯˜‰Ó†¯Ê†Û‚†˙‡ˆÂ‰†¯Á‡Ï†¨Ò˜ÏÙÓÈÒ

ƉȷÈίÓÓ†„Á‡Ï†˙Â˘È‚¯†Íφ‰Ú„Ȇ̇†‰Ù¯˙·†ÈØ˘Ó˙˘˙†Ï‡ ∫ÏÂÙÈˉ†˙ÏÁ˙‰†ÈÙφ‡Ù¯

·†ıÚÂÂȉφÈÏ

ȘÈφ

¨˙¯ÎÂÒÓ†

¯·Ú·†

˙Ï·Ò†

‡†

˙ØÏ·ÂÒ†

Íȉ†

̇†

Ɖ˜ÈÈÓ†

‡†

ÔÂȯ‰·†

Íȉ†

‡†

˙È¯˜‰†

Ï˘†

¯Á‡†

̉Èʆ

‡†

˘‡¯Ë˜†

¨‰Ó˜‡ς†

Ô‚Ω†

ÌÈÈÈÚ‰†

Ʈ̈چÁÓ†„˜Ù˙·†È˜ÈÏ©†Ì„‰†˙ίÚÓ†¨®˙ÈÓÁω ÌÈÈÂÈ˘Ï†

͢ÂÓÓ†

˘ÂÓÈ˘·†

̯‚φ

ÏÂÏÚ‰†

ϘÈÙÓ¯ÂÏΆ

ÏÈÎÓ†

¯È˘Î˙‰†

˙ÂÁ˙Ù˙‰Ï†

‡È·‰Ï†

ÏÂÏÚ†

ÌÈÈËÂÈ·ÈË‡†

ÌÈ¯È˘Î˙·†

͢ÂÓÓ†

˘ÂÓÈ˘†

ÆÌ„‰†

˙·¯˜†

ÌÈ˙ÈÚφ

Âʆ

‰Ù¯˙·†

˘Ó˙˘‰Ï†

Ôȇ†

Æ˙ÂȯËÙ†

ÏÏÂΆ

ÌÈ„ÈÓÚ†

ÌÈʆ

˘È†

͢ÂÓÓ†

˘ÂÓÈ˘†

Ï˘†

Ìȯ˜Ó·†

ƇÙ¯·†

ıÚÂÂȉφ

ÈÏ·†

˙΢ÂÓÓ†

‰Ù˜˙†

Íȉ†

̇†

ÆÈÈÚ†

ÍÂ˙†

ıÁφ

˙˜È„·†

¯Â·Úφ

ÌÈÈÈÚ†

‡Ù¯†

ψ‡†

·˜ÚÓ·†

ÈÙφ

‡Ù¯φ

ÍÎ≠ÏÚ†

ÚȄ‰φ

ÍÈÏÚ†

¨È‰˘ÏΆ

‰Ù¯˙φ

‡†

‰˘ÏΆ

ÔÂÊÓφ

˙ÂÚÙ˘‰Ï†

„ÁÂÈÓ·†

ÌÈ˘È‚¯†

ÌÈÈ˙˘†

ÏȂφ

˙Á˙Ó†

ÌÈ„ÏÈ

ƉÙ¯˙‰†

‰Ù¯˙†‰„ÈÓ·†ÆȇÂÂφ˙ÂÚÙÂ˙φÈÂÎÈÒ‰†¯·Â‚†ÔÎφÌÈÈÈÚφÌȄȇ¯ËÒ˜È˯˜ Æ˘ÂÓÈ˘‰†

˙‡¯Â‰†

ÏÚ†

„ÁÂÈÓ·†

„ÈÙ˜‰Ï†

‡Ù¯·†

ıÚÈÈ˙‰Ï†

˘È†

Ô˘†

„ÏÈφ

‰Ó˘¯†

˙¯·‚‰Ï†˘˘ÁÓ†¨Ú‚Ó†˙¢„Ú†‰Ø·ÈίӆÍȉ˘†

Ȉ¯˘†

ÔÓʉ†

͢Óφ

¯˘‡·†

ÌÈÈÈÚ‰†

‡Ù¯†

ÌÚ†

ıÚÈÈ˙‰Ï†

˘È†

Æ̉ÈÊφ

ÔÂÎÈÒ‰ ÆÚ‚Ó‰†˙¢„Ú†˙·Î¯‰Ï†ÛÂËÙˉ†ÔÈ·†ÔÈ˙Ó‰Ï ‰Ê†

˙¯Ó‚†

̇†

‡†

¨˙ÙÒÂ†

‰Ù¯˙†

˙ØÏËÂ†

Íȉ†

̇†

∫˙ÂÈ˙Ù¯˙≠ÔÈ

·†

ÌÈÂÎÈÒ†

ÚÂÓφ

ȄΆ

ÏÙËÓ‰†

‡Ù¯φ

Á„φ

ÍÈÏÚ†

¨˙¯Á‡†

‰Ù¯˙·†

ÏÂÙȈ

˙ˆ·˜‰Ó†

˙ÂÙ¯˙†

È·‚φ

„ÁÂÈÓ·†

¨˙ÂÈ˙Ù¯˙≠ÔÈ·†

˙·‚˙Ó†

ÌÈÚ·Â‰†

˙ÂÏÈÚÈ≠ȇ†

Chlor

amphenicol 2.00

xamethasone sodium phosphate

0.25

olym

yxin B sulphate

2500

units Chlor

amphenicol De

xamethasone sodium phosphate P

olym

∑¥μμ±Æ∞π±±

PATIENT PACKAGE INSERT IN ACCORDANCE WITH T

H

E

P

H

A

R

M

A

C

IS

T

S

’R

E

G

U

L

A

T

IO

N

S

(P

R

E

P

A

R

A

T

IO

N

S

)-

1

9

8

The dispensing of this medicine requires a ph

Read this package insert car

efully in its entir

ety befor

The format of this leaflet was determined by the Ministry of Health

and its content was checked and appr

TAROCIDIN D

e Drops Composition: Each ml of

arocidin D Eye drops contains: Chloramphenicol 2.00

Dexamethasone sodium phosphate

0.25 mg P

olymyxin B sulphate

2500 units The pr

eparation also contains: Bor

ic acid, sodium bor

, meth

ylpar

aben, prop

ylpar

aben, w

ater f

Therapeutic gr

oup:

Chloramphenicol is an antibiotic. Dexamethasone sodium phosphate is a cor

olymyxin B sulphate is an aminoglycoside antibiotic. Indications:

This medicine is indicated for the treatment of serious ocular infections due to strains of microorganisms susceptible to chloramphenicol and/or polymyxin B sulphate. When should the preparation not be used? Do not use this medicine in cases of fungal, viral, herpes simplex eye infections, after removal of a corneal foreign body or if you are suf

or have suf

fered in the past from ocular tuberculosis. Do not use this medicine if you are sensitive to any of its ingredients. Do not use this medicine without consulting a ph

ysician bef

star

ting treatment:

If you are pregnant or breastfeeding. If you are suf

fering, or have suf

fered in the past, from diabetes

function of: the eyes (e.g. glaucoma, cataract or any other inf

cornea or conjunctiv

a), the blood system (bone marrow dysfunction). W

arnings:

This medicine contains chloramphenicol which in prolonged use may cause haematological changes. Prolonged use of antibiotics may result in overgrowth of non-susceptible organisms, including fungi. Do not use this medicine frequently

, or for a long period, without consulting a ph

ysician. During prolonged treatment, y

ou should be under the sur

of an ophthalmologist and undergo intraocular pressure test. If you are sensitive to any type of food or medicine, inform your ph

commencing treatment with this medicine.

Children belo

may be especially sensitive to the ef

fects of ophthalmic corticosteroids. This may increase the chance of side ef

fects.

prescribed for a young child, the ph

instructions should be followed carefully

you are wearing contact lenses, because of the increased r

Consult your ophthalmologist regarding the desired time interval between insertion of the drops and wearing the contact lenses. Drug interactions:

If you are taking another drug concomitantly or if you have just finished treatment with another medicine, inform the attending ph

ysician, in order to prevent hazards or lack of ef

interactions.

This is especially important for medicines belonging to the following groups: bone marrow suppressants, antiglaucoma agents, anticholinergics

, especially atropine

, and any other ophthalmic medicine.

Side eff

ects:

In addition to the desired ef

reactions may occur during the course of using this medicine. Ef

fects that r

equir

e special attention:

or any other sign of irritation not present before therapy

elevated intraocular pressure (rare): stop treatment and consult a physician. Pale skin, sore throat, fever

, unusual bleeding, tiredness or weakness (rare): stop treatment and consult a physician (these ef

after completing treatment).

Visual disturbances

(rare): stop treatment and consult y

our physician immediately! In the event that you experience side ef

fects not mentioned in this leaflet, or if there is a change in your general health, consult your ph

ysician immediately

Ad

ver

se reactions and drug interactions in c

Parents must inform the attending ph

ysician about any side ef

well as any additional medicine being taken by the child! See above for details of special side ef

Dosa

g

e

:Dosage f

or adults and children is according to ph

instructions only

.Do not exceed the recommended dosage

If there is no improvement in your condition within 5-7 days, or if your condition deteriorates refer to your ph

ysician.

at specific time intervals as determined by the attending ph

forget to instill the drops at the specified time, apply as soon as you remember

, but never instill a double dose to compensate for a missed one! Attention:

Do not swallow!

This medicine is intended for external use only

Directions f

or use:

W

ash your hands thoroughly

.

lie down on a bed and with the aid of a finger pull the lower eyelid slightly away from the eye. Instill the medicine into the gap, and keep your eyes closed for 1-2 minutes.

ry not to blink.

T

o

pr

eye dr

ops

, take care not to allow the tip of the bottle to come into a contact with any surface including the finger or the eye itself, and close the bottle tightly after use. Do not use this medicine for more than one month after the bottle is first opened.

Ho

w can y

ou contrib

ute to the success of the treatment? Complete the full course of treatment as instructed by the ph

Even if there is an improvement in your health, do not discontinue use of this medicine before consulting your ph

A

v

o

id

p

o

is

o

n

in

g!

This medicine, and all other medicines, must be stored in a safe place out of the reach of children and/or infants, to avoid poisoning. If you have taken an overdose, or if a child has accidentally swallowed the medicine, proceed immediately to a hospital emergency room and bring the package of the medicine with you.

D

n

t

v

explicitly instructed to do so by a ph

ysician!

prescribed for the treatment of your ailment; in another patient, it could cause harm.

Do not give this medicine to r

e

n

tt

m

s

th

d

rk! Check the label and the dose

tim

you take your medicine. W

ear glasses if you need them. Stora

g

e

:Store in a refr

iger

ator (2-8

Use the product f

month after opening.

Even if kept in their original container and stored as recommended, medicines may be kept for a limited period only

note the expiry date of the medicine! In case of doubt, consult the pharmacist who dispensed the medicine to you.

Do not store dif

the same package. License n

umber:

1645.21224 Man

ufacturer:

T

aro Pharmaceutical Industries Ltd., P.O.B. 10347, Haifa Bay 261

מוצרים דומים

חיפוש התראות הקשורות למוצר זה

צפו בהיסטוריית המסמכים

שתף מידע זה